Web Date: August 9, 2017
GSK to end neuroscience R&D in China
It wasn’t long ago that GlaxoSmithKline’s Shanghai lab led the firm’s research efforts in neurological diseases including Parkinson’s, multiple sclerosis, and Alzheimer’s. Now, after years of setbacks in China, the company is ending neuroscience R&D in Shanghai.
“Following a portfolio review and prioritization, we have decided to close our neuroscience R&D center in Shanghai and move key programs to our global R&D hub in Upper Providence [Pa.] in the U.S., where they will benefit from . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society